Chart, page-56

These chart green predictions are as reliable as the D effect with his announcements:

“
14 June 2018
ATL1103/atesidorsen Early Access Program – Progress Update
Antisense Therapeutics Limited (“ANP” or “the Company” is pleased to provide an update on its progress to initiate an ATL1103 (also referred to as atesidorsen) Early Access Program (“EAP” for the treatment of acromegaly patients within select countries of the European Union, those initially planned being the Netherlands, Germany and .........
..............In parallel, the Company with its partner, leading Early Access provider myTomorrows (Amsterdam, The Netherlands), is progressing work for the documentation required for the regulatory approvals to supply atesidorsen product under the EAP. Alongside this documentation, the requisite Quality Assurance and Pharmacovigilance programs are being established and associated agreements are being finalised for execution. The regulatory approval and reimbursement processes can commence following product launch by myTomorrows which is after labeled product is in the myTomorrow’s warehouse and is released by myTomorrow’s Quality Person for the EAP and all the regulatory documentation is ready.
The activities necessary to initiate atesidorsen EAP treatments are anticipated to be completed ,or in place by end of 3’Q’18, as previously advised, with reimbursement approvals anticipated to come through on a country by country basis after the relevant regulatory approvals.

16 July 2018
ANP initiates ATL 1102 Phase II clinical trial in Duchenne Muscular Dystrophy.
Antisense Therapeutics (“ANP” or the “Company” is pleased to advise of the initiation of a Phase II clinical trial of its immunomodulatory therapy"...............................
...........An initiation meeting with trial investigators, coordinators, clinical project managers, nurses and other key personnel involved in the study has been held at the trial site at the RCH and patient recruitment is now to proceed, led by the Principal Investigators Dr Ian Woodcock, a Neuromuscular Fellow at the RCH and Professor Monique Ryan, Director of the Neurology Department at RCH..................... etc etc

29 August 2018
First patient dosed in Phase II clinical trial in Duchenne Muscular Dystrophy
Antisense Therapeutics (“ANP” or the “Company” today announced dosing of the first patient in a Phase II clinical trial of its immunomodulatory therapy, ATL1102, in patients with Duchenne Muscular Dystrophy (DMD)..................etc etc

But do not worry due to chart, announcements, D’ effect and more then anything thanks to the moon crossing the sixth constellation (or maybe the eighth ? well doesn’t matter one of them) together with the sun light now
in day light saving period tomorrow will be a GREEN DAY. ..............
Good night my fellow s.h.